Related references
Note: Only part of the references are listed.The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type2 diabetes
N. Matikainen et al.
DIABETIC MEDICINE (2013)
Liraglutide: short-lived effect on gastric emptyingulong lasting effects on body weight
J. Jelsing et al.
DIABETES OBESITY & METABOLISM (2012)
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
Michael Horowitz et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
ELEVATED AMYLASE AND LIPASE LEVELS IN PATIENTS USING GLUCAGONLIKE PEPTIDE-1 RECEPTOR AGONISTS OR DIPEPTIDYL-PEPTIDASE-4 INHIBITORS IN THE OUTPATIENT SETTING
Howard M. Lando et al.
ENDOCRINE PRACTICE (2012)
The Once-Daily Human Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Improves Postprandial Glucose Levels in Type 2 Diabetes Patients
Anne Flint et al.
ADVANCES IN THERAPY (2011)
The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
Christoph Kapitza et al.
ADVANCES IN THERAPY (2011)
Effects of Nutrients on Postprandial Lipemia
Denis Lairon et al.
CURRENT VASCULAR PHARMACOLOGY (2011)
Methods to Study Postprandial Lipemia
Teik Chye Ooi et al.
Current Vascular Pharmacology (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies
Steven P. Marso et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
A. J. Tremblay et al.
DIABETES OBESITY & METABOLISM (2011)
Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia
Robert H. J. Bandsma et al.
ATHEROSCLEROSIS (2010)
Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
Eric A. Schwartz et al.
ATHEROSCLEROSIS (2010)
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Mathijs C. Bunck et al.
ATHEROSCLEROSIS (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Postprandial lipaemia, oxidative stress and endothelial function: a review
J. P. Wallace et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein
Lene S. Mortensen et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2009)
Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
ANNALS OF PHARMACOTHERAPY (2009)
The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
N. Tentolouris et al.
CURRENT MEDICINAL CHEMISTRY (2009)
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
The effect of different protein hydrolysate/carbohydrate mixtures on postprandial glucagon and insulin responses in healthy subjects
M. Claessens et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2009)
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
Ralph A. DeFronzo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism
Ioanna Eleftheriadou et al.
CURRENT DIABETES REVIEWS (2008)
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Borge G. Nordestgaard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
M. Hanefeld
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
Determination of apolipoprotein B-48 in serum by a sandwich ELISA
M Kinoshita et al.
CLINICA CHIMICA ACTA (2005)
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
KB Degn et al.
DIABETES (2004)
Diabetic dyslipidaemia: from basic research to clinical practice
MR Taskinen
DIABETOLOGIA (2003)
Raising an isolated low HDL-C level: Why, how, and when?
M Miller
CLEVELAND CLINIC JOURNAL OF MEDICINE (2003)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study
M Willems et al.
DIGESTIVE DISEASES AND SCIENCES (2001)
Share Paper
